These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 33891265)

  • 1. Monitoring PSMA Responses to ADT in Prostate Cancer Patient-Derived Xenograft Mouse Models Using [
    Roy J; White ME; Basuli F; Opina ACL; Wong K; Riba M; Ton AT; Zhang X; Jansson KH; Edmondson E; Butcher D; Lin FI; Choyke PL; Kelly K; Jagoda EM
    Mol Imaging Biol; 2021 Oct; 23(5):745-755. PubMed ID: 33891265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.
    Chen Y; Pullambhatla M; Foss CA; Byun Y; Nimmagadda S; Senthamizhchelvan S; Sgouros G; Mease RC; Pomper MG
    Clin Cancer Res; 2011 Dec; 17(24):7645-53. PubMed ID: 22042970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simplified Methods for Quantification of
    Jansen BHE; Yaqub M; Voortman J; Cysouw MCF; Windhorst AD; Schuit RC; Kramer GM; van den Eertwegh AJM; Schwarte LA; Hendrikse NH; Vis AN; van Moorselaar RJA; Hoekstra OS; Boellaard R; Oprea-Lager DE
    J Nucl Med; 2019 Dec; 60(12):1730-1735. PubMed ID: 31000583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial [18F]DCFPyL PET/CT in treatment-naïve prostate cancer: correlation with post-ADT PSA outcomes and recurrence.
    Li Y; Wang S; Zhao S; Zhao P; Huang S; Li K; Han S; Tian C; Li X; Shi B; Li X
    Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2458-2466. PubMed ID: 38563882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective Comparison of PET Imaging with PSMA-Targeted
    Rowe SP; Li X; Trock BJ; Werner RA; Frey S; DiGianvittorio M; Bleiler JK; Reyes DK; Abdallah R; Pienta KJ; Gorin MA; Pomper MG
    J Nucl Med; 2020 Feb; 61(2):183-188. PubMed ID: 31451492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Prostate-Specific Membrane Antigen (PSMA) with F-18-Labeled Compounds: the Influence of Prosthetic Groups on Tumor Uptake and Clearance Profile.
    Bouvet V; Wuest M; Bailey JJ; Bergman C; Janzen N; Valliant JF; Wuest F
    Mol Imaging Biol; 2017 Dec; 19(6):923-932. PubMed ID: 28639122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraindividual Comparison of
    Giesel FL; Will L; Lawal I; Lengana T; Kratochwil C; Vorster M; Neels O; Reyneke F; Haberkon U; Kopka K; Sathekge M
    J Nucl Med; 2018 Jul; 59(7):1076-1080. PubMed ID: 29269569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer.
    Dietlein M; Kobe C; Kuhnert G; Stockter S; Fischer T; Schomäcker K; Schmidt M; Dietlein F; Zlatopolskiy BD; Krapf P; Richarz R; Neubauer S; Drzezga A; Neumaier B
    Mol Imaging Biol; 2015 Aug; 17(4):575-84. PubMed ID: 26013479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective Evaluation of
    Gaur S; Mena E; Harmon SA; Lindenberg ML; Adler S; Ton AT; Shih JH; Mehralivand S; Merino MJ; Wood BJ; Pinto PA; Mease RC; Pomper MG; Choyke PL; Turkbey B
    AJR Am J Roentgenol; 2020 Sep; 215(3):652-659. PubMed ID: 32755168
    [No Abstract]   [Full Text] [Related]  

  • 10. Semiquantitative Parameters in PSMA-Targeted PET Imaging with [
    Werner RA; Bundschuh RA; Bundschuh L; Lapa C; Yin Y; Javadi MS; Buck AK; Higuchi T; Pienta KJ; Pomper MG; Lodge MA; Gorin MA; Rowe SP
    Mol Imaging Biol; 2020 Feb; 22(1):190-197. PubMed ID: 31140110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repeatability of Quantitative
    Jansen BHE; Cysouw MCF; Vis AN; van Moorselaar RJA; Voortman J; Bodar YJL; Schober PR; Hendrikse NH; Hoekstra OS; Boellaard R; Oprea-Lager DE
    J Nucl Med; 2020 Sep; 61(9):1320-1325. PubMed ID: 31924729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer.
    Rowe SP; Macura KJ; Mena E; Blackford AL; Nadal R; Antonarakis ES; Eisenberger M; Carducci M; Fan H; Dannals RF; Chen Y; Mease RC; Szabo Z; Pomper MG; Cho SY
    Mol Imaging Biol; 2016 Jun; 18(3):411-9. PubMed ID: 27080322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [
    Dietlein F; Mueller P; Kobe C; Endepols H; Hohberg M; Zlatopolskiy BD; Krapf P; Heidenreich A; Neumaier B; Drzezga A; Dietlein M
    Mol Imaging Biol; 2021 Apr; 23(2):277-286. PubMed ID: 33006028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flare on [
    Malaspina S; Ettala O; Tolvanen T; Rajander J; Eskola O; Boström PJ; Kemppainen J
    Eur J Nucl Med Mol Imaging; 2023 Jan; 50(2):613-621. PubMed ID: 36161511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective Evaluation of
    Song H; Harrison C; Duan H; Guja K; Hatami N; Franc BL; Moradi F; Aparici CM; Davidzon GA; Iagaru A
    J Nucl Med; 2020 Apr; 61(4):546-551. PubMed ID: 31628216
    [No Abstract]   [Full Text] [Related]  

  • 16. Semiquantitative Parameters in PSMA-Targeted PET Imaging with
    Li X; Rowe SP; Leal JP; Gorin MA; Allaf ME; Ross AE; Pienta KJ; Lodge MA; Pomper MG
    J Nucl Med; 2017 Jun; 58(6):942-946. PubMed ID: 27932557
    [No Abstract]   [Full Text] [Related]  

  • 17. Intra-individual comparison of
    Ferreira G; Iravani A; Hofman MS; Hicks RJ
    Cancer Imaging; 2019 May; 19(1):23. PubMed ID: 31092293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer.
    Szabo Z; Mena E; Rowe SP; Plyku D; Nidal R; Eisenberger MA; Antonarakis ES; Fan H; Dannals RF; Chen Y; Mease RC; Vranesic M; Bhatnagar A; Sgouros G; Cho SY; Pomper MG
    Mol Imaging Biol; 2015 Aug; 17(4):565-74. PubMed ID: 25896814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Prospective Study on
    Rousseau E; Wilson D; Lacroix-Poisson F; Krauze A; Chi K; Gleave M; McKenzie M; Tyldesley S; Goldenberg SL; Bénard F
    J Nucl Med; 2019 Nov; 60(11):1587-1593. PubMed ID: 30979820
    [No Abstract]   [Full Text] [Related]  

  • 20. Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer.
    Aggarwal R; Wei X; Kim W; Small EJ; Ryan CJ; Carroll P; Cooperberg M; Evans MJ; Hope T
    Eur Urol Oncol; 2018 May; 1(1):78-82. PubMed ID: 31100231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.